Skip to Main Content

Good morning, everyone, and how are you today? The sun is trying to peek through a muggy haze descending this morning on the Pharmalot campus, where the official mascot is hunting for rabbits, and assorted birds and bugs can be heard in the distance. As for us, we are immersed in our usual routine of foraging for interesting items and brewing cups of stimulation. It is, after all, another busy day. No doubt, it is the same for you. So here are some tidbits to help you along. Hope today proves successful, and keep in touch. …

The Food and Drug Administration has changed the prescribing label for the controversial Biogen (BIIB) Alzheimer’s drug and narrowed its recommended use to patients with milder forms of the disease, STAT reports. Biogen and the FDA described the Aduhelm label update as a clarification meant to better reflect data from clinical trials. But the move will also be seen as the FDA yielding to outside criticism that the recent approval — just one month ago — was overly permissive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment